Recurrence of Idiopathic Orbital Inflammation: An 11-year Retrospective Study.

IF 0.5 Q4 OPHTHALMOLOGY Middle East African Journal of Ophthalmology Pub Date : 2024-06-14 eCollection Date: 2023-04-01 DOI:10.4103/meajo.meajo_225_21
Neni Anggraini, Nurjati C Siregar, Rita S Sitorus
{"title":"Recurrence of Idiopathic Orbital Inflammation: An 11-year Retrospective Study.","authors":"Neni Anggraini, Nurjati C Siregar, Rita S Sitorus","doi":"10.4103/meajo.meajo_225_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The high recurrence rate of idiopathic orbital inflammation (IOI) has been reported. This study aims to determine existing predictive factors for the recurrence of IOI.</p><p><strong>Methods: </strong>This was an 11-year retrospective study with at least a 12-month follow-up. Fifty patients with biopsy-proven IOI admitted between 2006 and 2017 at our tertiary hospital were observed. We compared the clinical characteristics, histopathological profile, and biomarker expressions (mast cell, immunoglobulin G4, tumor necrosis factor-alpha, and transforming growth factor-beta) of 16 patients with recurrence (Group I) and 34 patients with no recurrence (Group II). Statistical comparison and multivariate analysis were performed to establish the predictive factors.</p><p><strong>Results: </strong>We discovered five recurrence predictive factors: presentation of proptosis (odds ratio [OR] 4.96, 95% confidence interval [CI] 1.36-18.03), visual impairment (OR 15, 95% CI 1.58-142.72), extraocular muscle (EOM) restriction (OR 3.86, 95% CI 1.07-13.94), nonanterior involvement (OR 7.94, 95% CI 1.88-33.5), and corticosteroid (CS) alone treatment (OR 7.20, 95% CI 1.87-27.8). On multivariate analysis, nonanterior involvement and CS alone treatment were validated as predictive factors (area under the curve = 0.807 [95% CI 0.69-0.92]). Histopathological profile and biomarker expressions were not associated with recurrence. However, there was a 22-fold higher recurrence risk for granulomatous-type patients given CS alone treatment.</p><p><strong>Conclusion: </strong>Unlike the five clinical characteristics mentioned, both histopathology and biomarker variables were not associated with recurrence. CS alone treatment for patients with nonanterior involvement or granulomatous type is proven to increase the risk of recurrence. Therefore, we suggest not giving CS without any combination treatment with other modalities for this group of patients.</p>","PeriodicalId":18740,"journal":{"name":"Middle East African Journal of Ophthalmology","volume":"30 2","pages":"89-97"},"PeriodicalIF":0.5000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238927/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East African Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/meajo.meajo_225_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The high recurrence rate of idiopathic orbital inflammation (IOI) has been reported. This study aims to determine existing predictive factors for the recurrence of IOI.

Methods: This was an 11-year retrospective study with at least a 12-month follow-up. Fifty patients with biopsy-proven IOI admitted between 2006 and 2017 at our tertiary hospital were observed. We compared the clinical characteristics, histopathological profile, and biomarker expressions (mast cell, immunoglobulin G4, tumor necrosis factor-alpha, and transforming growth factor-beta) of 16 patients with recurrence (Group I) and 34 patients with no recurrence (Group II). Statistical comparison and multivariate analysis were performed to establish the predictive factors.

Results: We discovered five recurrence predictive factors: presentation of proptosis (odds ratio [OR] 4.96, 95% confidence interval [CI] 1.36-18.03), visual impairment (OR 15, 95% CI 1.58-142.72), extraocular muscle (EOM) restriction (OR 3.86, 95% CI 1.07-13.94), nonanterior involvement (OR 7.94, 95% CI 1.88-33.5), and corticosteroid (CS) alone treatment (OR 7.20, 95% CI 1.87-27.8). On multivariate analysis, nonanterior involvement and CS alone treatment were validated as predictive factors (area under the curve = 0.807 [95% CI 0.69-0.92]). Histopathological profile and biomarker expressions were not associated with recurrence. However, there was a 22-fold higher recurrence risk for granulomatous-type patients given CS alone treatment.

Conclusion: Unlike the five clinical characteristics mentioned, both histopathology and biomarker variables were not associated with recurrence. CS alone treatment for patients with nonanterior involvement or granulomatous type is proven to increase the risk of recurrence. Therefore, we suggest not giving CS without any combination treatment with other modalities for this group of patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
特发性眼眶炎症复发:11年回顾性研究
目的:据报道,特发性眼眶炎(IOI)的复发率很高。本研究旨在确定特发性眼眶炎复发的现有预测因素:这是一项为期 11 年的回顾性研究,随访至少 12 个月。我们观察了 2006 年至 2017 年期间在本三级医院住院的 50 例经活检证实的 IOI 患者。我们比较了16例复发患者(I组)和34例未复发患者(II组)的临床特征、组织病理学特征和生物标志物(肥大细胞、免疫球蛋白G4、肿瘤坏死因子-α和转化生长因子-β)表达。通过统计比较和多变量分析确定了预测因素:我们发现了五个复发预测因素:出现突眼(几率比[OR]4.96,95% 置信区间[CI]1.36-18.03)、视力障碍(OR 15,95% CI 1.58-142.72)、眼外肌(EOM)受限(OR 3.86,95% CI 1.07-13.94)、非前部受累(OR 7.94,95% CI 1.88-33.5)和单纯皮质类固醇(CS)治疗(OR 7.20,95% CI 1.87-27.8)。在多变量分析中,非前部受累和单纯 CS 治疗被确认为预测因素(曲线下面积 = 0.807 [95% CI 0.69-0.92])。组织病理学特征和生物标志物表达与复发无关。然而,肉芽肿型患者仅接受CS治疗的复发风险要高出22倍:结论:与上述五个临床特征不同,组织病理学和生物标志物变量与复发无关。事实证明,对非前部受累或肉芽肿型患者单纯进行 CS 治疗会增加复发风险。因此,我们建议这类患者在没有与其他方法联合治疗的情况下不要进行 CS 治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
1
期刊介绍: The Middle East African Journal of Ophthalmology (MEAJO), published four times per year in print and online, is an official journal of the Middle East African Council of Ophthalmology (MEACO). It is an international, peer-reviewed journal whose mission includes publication of original research of interest to ophthalmologists in the Middle East and Africa, and to provide readers with high quality educational review articles from world-renown experts. MEAJO, previously known as Middle East Journal of Ophthalmology (MEJO) was founded by Dr Akef El Maghraby in 1993.
期刊最新文献
Pro re nata Treatment of Diabetic Macular Edema with Cycles of Three Injections of Anti-vascular Endothelial Growth Factor Injections. A Clinical Study on Severity of Dry Eye in Individuals with Pterygium at a Tertiary Hospital in South Kerala. A Novel Snake-chain Metal Probed Silicon Intubation Set for Nasolacrimal Duct Intubation: A Cadaveric Feasibility Study. A Population-based Study of the Prevalence of Cataract and Its Relationship with Smoking in the Northwest of Iran: The Azar Cohort Eye Study. Bilateral Acute Iris Transillumination Following Coronavirus Disease 2019 Infection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1